Paul Aguilar
Paul leads the Clinical Trials team’s strategic policy work and oversees their efforts to identify and build philanthropic investments and partnerships. The team aims to ensure that the U.S. Food and Drug Administration’s (FDA) approvals incentivize innovation by using clinically meaningful evidence, that trial data is publicly available and comparable across products, and that FDA is transparent and upholds its science-based gold standard for medical product review and regulation. The Clinical Trials team also works to ensure that the Center for Medicare and Medicaid Services aligns its coverage decisions with available clinical evidence.
Before joining Arnold Ventures, Paul served at FDA for 12 years, with over a decade spent in the Office of Legislation. There he led the team that worked on device, biologics, and tobacco issues. During his time in the Office of Legislation, Paul worked on two FDA user fee reauthorizations, legislative efforts regarding the regulation of laboratory developed tests, synthetic nicotine products, cell and gene therapies, as well as several cross-cutting initiatives such as the agency’s Zika and COVID responses, and ongoing efforts to modernize the regulation of artificial intelligence-enabled medical devices.
Paul received his master’s in public heath from the University of Texas Health Science Center in Houston and his bachelor’s from Stanford University.
He lives in Virginia with his wife and daughter. They enjoy exploring parks and restaurants in the DMV area. In his free time, Paul tries to squeeze in a round of golf as often as possible.
